Our lead product, EYS606 is the first non-viral product that has the potential to treat NIU patients for 3 to 12 months following an electro-transfection procedure.

EYS606 uses a plasmid encoding for the production of a potent anti-TNFα. TNFα is a pro inflammatory cytokine that has been shown to play an important role in enhancing intraocular cytotoxic events in immune diseases, including uveitis.

EYS606 is expected to start a Phase I trial in H1 2017.

The Company expects the overall clinical development programme of EYS606 to follow a fast-track, considering that EYS606 has been granted an Orphan designation by the EMA for the treatment of NIU.


The objectives of the Phase I clinical trial are two-folds:

  • Establish the feasibility and safety of therapeutic plasmid electroporation in humans;
  • Achieve clinical efficacy proof of concept of sustained protein production in the eye, in the NIU indication


About NIU

Uveitis is the inflammation of the uvea, the pigmented layer that lies between the inner retina and the outer fibrous layer composed of the sclera and cornea. The uvea consists of the middle layer of pigmented vascular structures of the eye and includes the iris, ciliary body, and choroid.

Uveitis is classified anatomically into anterior, intermediate, posterior and panuveitic forms - based on the part of the eye primarily affected.

  • Anterior uveitis is the inflammation of the anterior chamber and iris. Anywhere from two-thirds to 90% of uveitis cases are anterior in location. This condition can occur as a single episode and subside with proper treatment or may take on a recurrent or chronic nature
  • Intermediate uveitis is the inflammation of cells in the vitreous cavity
  • Posterior uveitis or chorioretinitis is the inflammation of the retina and choroid
  • Pan-uveitis is the inflammation of all layers of the uvea


The lead indication pursued by Eyevensys is non-infectious intermediate and posterior uveitis (NIU).

Representing over 10% of uveitis cases, it is the 4th cause of blindness, and is considered a rare disease afflicting 3.3 to 3.8 in 10 000 people, i.e. 250 000 patients in North America and Europe. The market is estimated at over €250 million, growing at a rate of 6.5% a year.